<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720457</url>
  </required_header>
  <id_info>
    <org_study_id>HRAIN01-NHL01</org_study_id>
    <secondary_id>CTR20181354</secondary_id>
    <nct_id>NCT03720457</nct_id>
  </id_info>
  <brief_title>Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.</brief_title>
  <official_title>A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hrain Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hrain Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the&#xD;
      treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and&#xD;
      follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of&#xD;
      fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with relapsed/refractory CD19-positive Diffuse Large B-cell Lymphoma and&#xD;
      Follicular Lymphoma can participate if all eligibility criteria are met.Tests required to&#xD;
      determine eligibility include disease assessments, a physical exam, Electrocardiograph,&#xD;
      CT/MRI , and blood draws.Participants receive chemotherapy prior to the infusion of CD19 CAR+&#xD;
      T cells. After the infusion, participants will be followed for side effects and effect of&#xD;
      CD19 CAR+ T cells. Study procedures may be performed while hospitalized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 5.0</measure>
    <time_frame>2 years post infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of CAR-positive T cells in circulation</measure>
    <time_frame>2 years post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of CAR-positive T cells infiltrated into lymphoma tissue</measure>
    <time_frame>2 years post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall remission rate including complete response and Partial response defined by the standard response criteria for malignant lymphoma.</measure>
    <time_frame>90 days post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response after administration</measure>
    <time_frame>90 days post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival after administration</measure>
    <time_frame>90 days post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival after administration</measure>
    <time_frame>90 days post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The immunogenicity of Human CD19 targeted T Cells Injection. (HAMA detection of human anti-mouse antibody)</measure>
    <time_frame>2 years post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>CD19-positive</condition>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Human CD19 targeted T Cells Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human CD19 targeted T Cells Injection</intervention_name>
    <description>Autologous genetically modified anti-CD19 CAR transduced T cells</description>
    <arm_group_label>Human CD19 targeted T Cells Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male or female subjects with CD19+ B cell lymphomas who have a limited prognosis (several&#xD;
        months to &lt;2 year survival) with currently available therapies will be enrolled.&#xD;
&#xD;
          1. 18 to 70 Years Old, Male and female;&#xD;
&#xD;
          2. Expected survival &gt; 12 weeks;&#xD;
&#xD;
          3. Clinical performance status of ECOG score 0-1;&#xD;
&#xD;
          4. Pathology demonstrated that CD19-positive B-cell non-Hodgkin's lymphoma and who meet&#xD;
             one of the following conditions:&#xD;
&#xD;
               1. Relapsed and refractory CD19-positive Diffuse large B-cell lymphoma and&#xD;
                  Follicular lymphoma: patients previously received at least first-line and second-&#xD;
                  line treatment and fail to achieve CR;&#xD;
&#xD;
               2. Disease recurrence after stem cell transplantation, and at least 1 years after&#xD;
                  stem cell transplantation.&#xD;
&#xD;
          5. It can establish the venous access required for collection, satisfying hemoglobin ≥ 70&#xD;
             g / L, neutrophils ≥ 1.0 × 10 ^ 9 / L, platelets ≥ 50 × 10 ^ 9 / L. Mononuclear cell&#xD;
             collection can be determined by the investigators;&#xD;
&#xD;
          6. At least 1 measurable tumor foci according to the 2014 Lugano treatment response&#xD;
             criteria;&#xD;
&#xD;
          7. Liver, kidney and cardiopulmonary functions meet the following requirements:&#xD;
&#xD;
               1. Serum creatinine ≤ 1.5 × ULN;&#xD;
&#xD;
               2. Left ventricular ejection fraction &gt;50%, no pericardial effusion and no pleural&#xD;
                  effusion (ECHO examination);&#xD;
&#xD;
               3. Baseline oxygen saturation &gt; 92%;&#xD;
&#xD;
               4. Total bilirubin ≤ 1.5 × ULN;&#xD;
&#xD;
               5. ALT and AST ≤ 3 × ULN.&#xD;
&#xD;
          8. Able to understand and sign the Informed Consent Document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the first 5 years before screening, there are malignant tumors other than diffuse&#xD;
             large B-cell lymphoma and follicular lymphoma, except for fully treated cervical&#xD;
             carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer&#xD;
             after radical surgery，and catheter carcinoma in situ after radical surgery;&#xD;
&#xD;
          2. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and&#xD;
             peripheral blood HBV DNA titer higher than the upper limit of detection; hepatitis C&#xD;
             virus (HCV) antibody positive and peripheral blood HCV RNA positive; human&#xD;
             immunodeficiency Viral (HIV) antibody positive; Positive syphilis test;&#xD;
&#xD;
          3. Any unstable systemic disease including, but not limited to, active infection (except&#xD;
             for local infection), unstable angina pectoris, cerebrovascular accident or transient&#xD;
             cerebral ischemia (within 6 months prior to screening), myocardial infarction (within&#xD;
             6 months prior to screening), congestive heart failure (New York Heart Association&#xD;
             [NYHA] classification ≥ III), severe arrhythmia , liver, kidney or metabolic disease&#xD;
             requiring medication;&#xD;
&#xD;
          4. Any other diseases could affect the outcome of this trial;&#xD;
&#xD;
          5. Any affairs could affect the safety of the subjects or outcome of this trial;&#xD;
&#xD;
          6. Pregnant or lactating women, or planned pregnancy during treatment or within 1 year&#xD;
             after treatment, or a male subject whose partner plans pregnancy within 1 year of&#xD;
             their cell transfusion;&#xD;
&#xD;
          7. Active or uncontrollable infection requiring systemic therapy within 14 days prior to&#xD;
             enrollment;&#xD;
&#xD;
          8. Subjects who are receiving systemic steroid treatment and requiring long-term systemic&#xD;
             steroid treatment during the treatment as determined by the investigator before&#xD;
             screening (except inhalation or topical use); And subjects treated with systemic&#xD;
             steroids (except inhalation or topical use) within 72h prior to cell transfusion;&#xD;
&#xD;
          9. Received CAR-T treatment or other gene therapies before enrollment;&#xD;
&#xD;
         10. Patients with symptoms of central nervous system or brain metastasis or have received&#xD;
             treatment for central nervous system or brain metastasis (radiotherapy, surgery or&#xD;
             other treatment) within 3 months before enrollment;&#xD;
&#xD;
         11. Subject suffering disease affects the understanding of informed consent or comply with&#xD;
             study protocol;&#xD;
&#xD;
         12. The investigators consider other conditions unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongliang Fang, Dr.</last_name>
    <phone>021-58552006</phone>
    <email>fanghongliang@dashengbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingming Wang, M.D.</last_name>
      <phone>0791-86300483</phone>
      <email>wqming222@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Liu, Professor</last_name>
      <phone>021-60267405</phone>
      <email>Liu.peng@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affilicated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Songfu Jiang</last_name>
      <phone>0577-55578023</phone>
      <email>jiangsongfu@189.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19</keyword>
  <keyword>CAR-T</keyword>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Relapsed /Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

